In Vitro Activities of BMS-207147 against Over 600 Contemporary Clinical Bloodstream Isolates of Candida Species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America-Reference-Cited by-同舟云学术

In Vitro Activities of BMS-207147 against Over 600 Contemporary Clinical Bloodstream Isolates of Candida Species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America

Published:1999-09 Issue:9 Volume:43 Page:2236-2239
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Diekema D. J.¹,Pfaller M. A.¹,Messer S. A.¹,Houston A.¹,Hollis R. J.¹,Doern G. V.¹,Jones R. N.¹,

Affiliation:

1. Medical Microbiology Division, Department of Pathology, University of Iowa College of Medicine, Iowa City, Iowa

Abstract

ABSTRACT We compared the in vitro activity of BMS-207147, an investigational triazole, with those of itraconazole and fluconazole against 613 clinical bloodstream isolates of Candida spp. collected from SENTRY participating hospitals during 1997 and 1998. Overall, BMS-207147 was the most active azole against all Candida spp. While both BMS-207147 and itraconazole displayed a stepwise decrease in activity against isolates for which the fluconazole MICs were elevated, BMS-207147 had two- to fourfold greater activity than itraconazole both against Candida spp. that were dose-dependently fluconazole susceptible and against those that were fluconazole resistant.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.43.9.2236

Reference12 articles.

1. New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinozolinones.;Bartroli J.;J. Med. Chem.,1998

2. Espinel-Ingroff A. Evaluation of antifungal susceptibility testing parameters for amphotericin B itraconazole voriconazole SCH56592 and BMS-207147 against Aspergillus spp. abstr. J-7 Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1998 452 American Society for Microbiology Washington D.C

3. Espinel-Ingroff A. Palacio A. Carrillo-Munoz A. In vitro activity of the new triazole BMS-207147 against Aspergillus spp. Candida spp. and emerging mold pathogens: a comparative study abstr. F-154 Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1998 271 American Society for Microbiology Washington D.C

4. In Vitro Activity of a New Oral Triazole, BMS-207147 (ER-30346)

5. Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of E1224 by leveraging a strategic partnership for the medicines creation against neglected tropical diseases;Parasitology International;2021-04

2. Potential of Ravuconazole and its Prodrugs as the New OralTherapeutics for Onychomycosis;Medical Mycology Journal;2016

3. Azoles as Effective Antifungal Agents: Trends, Scope and Relevance;The Natural Products Journal;2014-10-08

4. Madurella mycetomatis Is Highly Susceptible to Ravuconazole;PLoS Neglected Tropical Diseases;2014-06-19

5. In vitro Antifungal Activity of Ravuconazole Against Isolates of Dermatophytes and Candida Species from Patients with Dermatomycoses;Medical Mycology Journal;2014